The US Food and Drug Administration (FDA) has approved insulin glulisine (Apidra) to treat diabetes in children ages 4 and older, announced the drug's manufacturer, sanofi-aventis.
The US Food and Drug Administration has approved insulin glulisine (Apidra) to treat diabetes in children ages 4 and older, announced the drug's manufacturer, sanofi-aventis.
The approval is based on an FDA review of a 26-week, phase III, open-label study comparing Apidra with insulin lispro among 572 children ages 4 to 17 with type 1 diabetes. Changes in HbA1c were similar in both treatment groups (+0.10% for glulisine vs. +0.16% for lispro), as was postprandial glycemic control during endpoint.
Additionally, 7.2% of participants in the glulisine group and 8.1% of participants in the lispro group reported the adverse event of hypoglycemia, according to the manufacturer.
Anger hurts your team’s performance and health, and yours too
October 25th 2024Anger in health care affects both patients and professionals with rising violence and negative health outcomes, but understanding its triggers and applying de-escalation techniques can help manage this pervasive issue.